Store at -20°C

i6217

# SignalSilence® CDK5 siRNA II

300 μl
(100 transfections)



 Orders

 877-616-CELL (2355)
 orders@cellsignal.com

Support
877-678-TECH (8324)
info@cellsignal.com
Web
www.cellsignal.com

rev. 02/09/16




## Species Cross-Reactivity: H, M, R

Description: SignalSilence® CDK5 siRNA II from Cell Signaling Technology (CST) allows the researcher to specifically inhibit CDK5 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.

Background: Cyclin-dependent kinases (CDKs) are serine/ threonine kinases that are activated by cyclins and govern eukaryotic cell cycle progression. While CDK5 shares high sequence homology with its family members, it is thought mainly to function in postmitotic neurons to regulate the cytoarchitecture of these cells. Analogous to cyclins, the regulatory subunits p35 and p39 associate with and activate CDK5 despite the lack of sequence homology. CDK5 is ubiguitously expressed, with high levels of kinase activity detected primarily in the nervous system due to the narrow expression pattern of p35 and p39 in post-mitotic neurons. A large number of CDK5 substrates have been identified although no substrates have been specifically attributed to p35 or p39. Substrates of CDK5 include p35. PAK1. Src. catenin, tau, neurofilament-H, neurofilament-M, synapsin1, APP, DARPP32, PP1-inhibitor and Rb. p35 is rapidly degraded (T1/2 <20 min) by the ubiquitin-proteasome pathway (1). However, p35 stability increases as CDK5 kinase activity decreases, likely as a result of decreased phosphorylation of p35 at Thr138 by CDK5 (2). Proteolytic cleavage of p35 by calpain produces p25 upon neurotoxic insult, resulting in prolonged activation of CDK5 by p25. Accumulation of p25 is found in neurodegenerative diseases such as Alzheimer disease and amyotrophic lateral sclerosis (ALS) (3,4).

**Directions for Use:** CST recommends transfection with 100 nM CDK5 siRNA II 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.

**Quality Control:** Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.



Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence<sup>®</sup> Control siRNA (Unconjugated) #6568 (-), SignalSilence<sup>®</sup> COK5 siRNA I #6216 (+) or SignalSilence<sup>®</sup> CDK5 siRNA II (+), using CDK5 Antibody #2506 (upper) or  $\alpha$ -Tubulin (11H10) Rabbit mAb #2125 (lower). The CDK5 Antibody confirms silencing of CDK5 expression, while the  $\alpha$ -Tubulin (11H10) Rabbit mAb is used to control for loading and specificity of CDK5 siRNA.

#### Entrez-Gene ID #1020 Swiss-Prot Acc. #Q00535

**Storage:** CDK5 siRNA II is supplied in RNAse-free water. Aliquot and store at -20°C.

## Please visit www.cellsignal.com for a complete listing of recommended companion products.

### Background References:

(1) Dhavan, R. and Tsai, L.H. (2001) *Nat Rev Mol Cell Biol* 2, 749-59.

(2) Patrick, G.N. et al. (1998) J Biol Chem 273, 24057-64.

(3) Lee, M.S. et al. (2000) Nature 405, 360-4.

(4) Kusakawa, G. et al. (2000) J Biol Chem 275, 17166-72